Dr. Reddy's Laboratories Ltd.

BSE

Price on BSE 06 May,11:15 LIVE

1,283.00

+12.05

(+0.95%)

Volume :
13,809.00

Prev Close :
1,270.95

Day's H/L (Rs.) :
1,292.95 - 1,276.90

52wk H/L (Rs.) :
1,377.95 - 1,121.20

Mkt Cap (Rs. Cr) :
107,092.01

NSE

Price on NSE 06 May,11:43 LIVE

1,301.00

+29.80

(+2.34%)

Volume :
424,038.00

Prev Close :
1,271.20

Day's H/L (Rs.) :
1,301.30 - 1,277.10

52wk H/L (Rs.) :
1,379.70 - 1,129.40

Mkt Cap (Rs. Cr) :
0.00

Market News

Canada first G7 nation to okay Dr Reddy's generic version of semaglutide
Rediff.com 5 day(s) ago

Semaglutide Ruling Sparks Generic Pharma Boom
Rediff.com 24 Mar 2026

Vet killed by hippo during treatment at Shivamogga zoo
Rediff.com 20 Mar 2026

Multinational pharma cos, Indian drugmakers diverge to mutual gain: How win-win is it?
Rediff.com 11 Mar 2026

HUL tops sustainability rankings as India Inc deepens ESG focus
Rediff.com 19 Feb 2026

Report Card - Dr. Reddy's Laboratories Ltd.

PE Ratios

19.81

EPS (Rs.)

64.14

Sales (Rs. Cr)

4,282.70

Face Value (Rs.)

Net Profit Margin(%)

23.14

Last Bonus

1:1

Last Dividend(%)

800

Return on Average Equity

18.53

News for Dr. Reddy's Laboratories Ltd.

Dr. Reddy''s Semaglutide Injection Approved in Canada

Dr. Reddy''s gets Health Canada approval for generic semaglutide injection for type-2 diabetes. First generic approval in Canada.

Apr 29, 2026 10:14

Dr Reddy''s: US SEC Ends Investigation

US SEC concludes investigation into Dr Reddy''s. No enforcement action recommended after probe into improper payments allegations.

Feb 24, 2026 21:16

Dr Reddy''s Enters Hormone Replacement Therapy

Dr Reddy''s acquires Progynova & Cyclo-Progynova for USD 32.15 mn, entering the hormone replacement therapy market in India. Strengthens gynaecology portfolio.

Feb 19, 2026 08:58

Dr Reddy''s Q3 Profit Dips 14% to Rs 1,210 Cr

Dr Reddy''s Q3FY26 profit declines 14% to Rs 1,210 crore due to lower US sales. Revenue rises to Rs 8,727 crore. India sales up 19%.

Jan 21, 2026 18:20

Dr Reddy''s & Immutep Ink Cancer Drug Licensing Pact

Dr Reddy''s and Immutep collaborate to develop and commercialize Eftilagimod Alfa (Efti), a cancer medication, outside key markets.

Dec 08, 2025 14:49

More News for Dr. Reddy's Laboratories Ltd. »

News for Pharmaceuticals and health care

Vodafone Idea Shares Surge on Birla Appointment

Vodafone Idea stock jumps as Kumar Mangalam Birla becomes chairman. Ravinder Takkar steps down but remains as vice-chairman.

May 06, 2026 11:36

Rupee to Hit Rs 95/USD by End-2026: BMI Forecast

BMI forecasts Indian Rupee to trade around Rs 95 per USD by end-2026, influenced by Iran conflict and RBI intervention.

May 06, 2026 11:31

Biocon: Kiran Mazumdar-Shaw Names Niece as Successor

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon. Succession planning details and Claire's background revealed.

May 06, 2026 10:52

Stocks Rebound on Oil Price Dip, Iran Deal Hopes

Stock markets surge as oil prices fall amid US-Iran negotiation progress. Sensex, Nifty rally. Global cues positive.

May 06, 2026 10:07

Rupee Rises Against US Dollar on Iran Deal Hint

Rupee gains 23 paise to 94.95 against the US dollar as Brent crude falls after Trump hints at Iran deal. Sensex and Nifty rally.

May 06, 2026 10:04

More News »

Top News